Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06473871 for hypertrophic scar reduction after breast surgery scar revision
2012-004355-37Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2012
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EXC 001 in Hypertrophic Scar (HS) (2 arms), sponsored by Pfizer. Primary endpoint: Physician Global Assessment using Physician Overall Opinion of POSAS at Week 24. Started Dec 2012; status: completed.
02
Drugs
EXC 001
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on 2012-004355-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004355-37.